ABSTRACT
Drug repurposing is the focus of therapeutic testing from NPOs that support rare neurodegenerative diseases. The grants for drug repurposing are becoming larger and the timelines longer, as some Not-for-Profit Organizations (NPOs) start to think of drug repurposing in terms of market approval instead of off-label use. There are two significant reasons that NPOs have started to participate in drug repurposing. First, there is a huge funding gap in the generic drug repurposing market. Many NPOs have surveyed the market, discussed drug development with their science advisors and academic research partners, and come to the conclusion that adding drug repurposing to their de novo drug development research portfolios makes sense, especially since their mission is to improve patient healthcare outcomes as quickly as possible. One very common way that an NPO will find out about a drug repurposing idea is from clinical observations of clinicians treating patients who are associated with the NPO.
